Boosting p53 Helps Immune Cells Fight Melanoma

Early lab tests show treated T cells lasted longer and killed more melanoma cells, but no animal or human testing has been done yet.

Updated on Nov. 2, 2026 in Cancer

Clear glass culture flasks of pale amber liquid on a steel laboratory bench under a biosafety hood, with a pipette resting across one flask. — UCLA researchers found that temporarily boosting the protein p53 helped lab-grown human immune cells fight melanoma in early tests, though no animal or human studies have been done. AI Illustration. Upload story photo >

UCLA Health Jonsson Comprehensive Cancer Center researchers found that temporarily boosting the protein p53 helped immune T cells fight melanoma cells in laboratory tests. The findings, published in Frontiers in Immunology, apply to lab-grown human cells, so readers with melanoma or other cancers should not expect any change to care from this work yet.

Why it matters

Some cancer treatments modify a patient's T cells in a lab so they can recognize cancer before being returned to the body, but these cells can become exhausted and lose effectiveness. This study explores a way to keep those cells working longer, which could matter for future therapies, though it remains at a very early stage.

This is a laboratory study using human T cells treated in a dish, not in animals or people. The treated cells showed fewer signs of exhaustion and were significantly more effective at killing melanoma cells than untreated cells, but the study does not establish results beyond these lab conditions.

The players

UCLA Health Jonsson Comprehensive Cancer Center

A comprehensive cancer center at the University of California, Los Angeles, known for cancer research and patient care across multiple tumor types.

Frontiers in Immunology

A peer-reviewed open-access journal that publishes research on immune system biology and its role in disease.

The details

Researchers treated human T cells with navtemadlin, an experimental drug that temporarily increases the activity of p53, a protein that helps prevent cancer. The drug was added during the manufacturing step, when a patient's T cells are being prepared in the lab. In these conditions, the treated cells appeared to have more energy and were less worn out than untreated cells.

The study was published in Frontiers in Immunology and an article about it appeared on November 2, 2026.

Health Landscape

Engineered T-cell therapies have shown benefit in some blood cancers, but exhaustion of these cells has made them harder to apply to solid tumors such as melanoma. This lab study adds one possible approach to a field still working to keep these cells effective over time.

For now, this research does not change any cancer screening, treatment, or prevention recommendation. If you have melanoma or are considering a cell-based therapy, it is worth asking your oncologist about current options and how emerging research may or may not apply to your situation.

The takeaway

This early lab work suggests that keeping immune T cells active may improve their ability to fight cancer, but human testing is still years away. A helpful habit is to ask your oncologist which clinical trials are available if you are interested in newer cell-based therapies.